Celldex Therapeutics (NASDAQ:CLDX) Given a $19.00 Price Target at HC Wainwright

HC Wainwright set a $19.00 price objective on Celldex Therapeutics (NASDAQ:CLDX) in a research note released on Wednesday, May 8th, TipRanks reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

CLDX has been the topic of several other research reports. ValuEngine upgraded shares of Celldex Therapeutics from a hold rating to a buy rating in a report on Wednesday, May 1st. Zacks Investment Research downgraded shares of Celldex Therapeutics from a buy rating to a hold rating in a report on Thursday, January 24th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $12.38.

Celldex Therapeutics stock opened at $3.04 on Wednesday. The firm has a market cap of $41.99 million, a PE ratio of -0.45 and a beta of 4.13. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 0.02. Celldex Therapeutics has a 1-year low of $2.74 and a 1-year high of $11.63.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.01. The business had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.26 million. Celldex Therapeutics had a negative net margin of 729.59% and a negative return on equity of 45.09%. On average, research analysts expect that Celldex Therapeutics will post -4.8 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc grew its position in Celldex Therapeutics by 7.5% in the 3rd quarter. Vanguard Group Inc now owns 6,047,564 shares of the biopharmaceutical company’s stock worth $2,728,000 after purchasing an additional 421,700 shares during the last quarter. Vanguard Group Inc. grew its position in Celldex Therapeutics by 7.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,047,564 shares of the biopharmaceutical company’s stock worth $2,728,000 after purchasing an additional 421,700 shares during the last quarter. Renaissance Technologies LLC grew its position in Celldex Therapeutics by 26.6% in the 3rd quarter. Renaissance Technologies LLC now owns 5,343,599 shares of the biopharmaceutical company’s stock worth $2,410,000 after purchasing an additional 1,122,912 shares during the last quarter. BlackRock Inc. boosted its position in shares of Celldex Therapeutics by 6.2% during the 3rd quarter. BlackRock Inc. now owns 3,801,667 shares of the biopharmaceutical company’s stock valued at $1,715,000 after acquiring an additional 223,231 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Celldex Therapeutics by 1.5% during the 4th quarter. Two Sigma Investments LP now owns 1,741,075 shares of the biopharmaceutical company’s stock valued at $345,000 after acquiring an additional 25,859 shares in the last quarter. Hedge funds and other institutional investors own 21.30% of the company’s stock.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Featured Story: Google Finance Portfolio Workaround

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.